alexa A Direct Renin Inhibitor Aliskiren: Re-Evaluation of Effectiveness | Open Access Journals
ISSN: 2157-7609
Journal of Drug Metabolism & Toxicology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

A Direct Renin Inhibitor Aliskiren: Re-Evaluation of Effectiveness

Macit C1, Mercanoglu G2* and Mercanoglu F3

1Yeditepe University, Faculty of Pharmacy, Department of Clinical Pharmacy Istanbul-Turkey

2Biruni University, Faculty of Pharmacy, Department of Pharmacology Istanbul-Turkey

3Istanbul University, Istanbul Medical Faculty, Department of Cardiology Istanbul-Turkey

*Corresponding Author:
Dr. Guldem Mercanoglu
Biruni Universty, Faculty of Pharmacy
Department of Pharmacology Istanbul, Turkey
Tel: 90216 5780000
E-mail: [email protected]

Received date: May 02, 2015 Accepted date: July 09, 2015 Published date: July 16, 2015

Citation: Macit C, Mercanoglu G, Mercanoglu F (2015) A Direct Renin Inhibitor Aliskiren: Re-Evaluation of Effectiveness. J Drug Metab Toxicol 6:185. doi: 10.4172/2157-7609.1000185

Copyright: © 2015 Macit C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Drug Metabolism & Toxicology


The RAAS is an important pharmacologic target as the system is involved in cardiovascular (CV) and renovascular disease. Ang II is the key component of RAAS. The intervention to the RAAS can be achieved in different stages. While angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two big groups that target the RAAS, aliskiren a direct renin inhibitor that became clinically feasible in 2007 with the launch of aliskiren. In this review, we will discuss direct renin inhibition as a new concept for pharmacotherapy of hypertension and aliskiren, the first oral direct renin inhibitor, as a new class of antihypertensive drug based on new evidence.


Hypertension; Renin-angiotensin-aldesterone system; Aliskiren; Direct renin inhibitor; RAAS inhibitor


Pivotal role of the renin angiotensin aldosterone system (RAAS) both in the progression as well as the pathogenesis of cardiovascular disease such as hypertension, atherosclerosis, chronic heart failure, is undeniable [1]. The activation of the RAAS, which is initially regulatory and compensational, becomes disproportionate and uncontrollable by time, and hence triggers emergence of cardiovascular diseases. Key factor that determine the activation of the RAAS system is renin protease, which control the synthesis of angiotensin II (Ang II) from angiotensinogen. Ang II, produced from angiotensin I (Ang I) by angiotensin converting enzyme (ACE), is responsible for the complications mediated by Ang II receptor in the end organs such as vasoconstriction, hypertrophy and growth in vascular smooth muscles in the cardiovascular diseases.

Although the activity of renin is the basic rate-limiting step in the RAAS, the initial drug development goals have been directed to the subsequent steps and successful clinical results were obtained from clinical studies conducted with angiotensin converting enzyme inhibitors (ACEIs) and then angiotensin receptor blockers (ARBs) [2]. Numerous studies have shown that ACEIs and ARBs lead to significant decrease in morbidity and mortality of cardiovascular diseases, such as hypertension and heart failure. However, it is not possible to say that the final point is reached in the RAAS blockade. A complete blockade of the RAAS is not provided with ACEIs and ARBs. Such agents cause increase in renin activity by "feedback" mechanism. On the other hand, the effects of ACEIs on bradykinin negatively affect the side effect profile of these agents. Above all, the clinical benefits with both ACEIs and ARBs are significant, yet insufficient. Considering that the renin activity is the main controlling step of the RAAS, inhibition of the renin will theoretically provide a more complete and effective inhibition of RAAS. In this review pharmacokinetic and clinical data regarding Aliskiren, the first direct renin inhibitor (DRI) with accepted clinical utility, will be reviewed based on new evidence.

Renin Angiotensin Aldosteron System

Basically, RAAS is a coordinated hormonal cascade that governs the cardiovascular, renal and adrenal functions by regulating fluid and electrolyte balance as well as arterial pressure [3,4].

Secretion of renin is the first step in RAAS cascade and, importantly, also the rate-limiting step, (Figure 1) [5,6]. Renin is secreted, in response to a variety of stimuli, from kidneys but the only known physiological substrate for renin in the plasma is angiotensinogen. Renin acts on the angiotensinogen to form angiotensin I (Ang I) that is subsequently converted to the biologically active angiotensin II (Ang II) by the help of angiotensin converting enzyme (ACE) [7].


Figure 1: Site of action of four classes of antihypertensive drugs that block RAAS: ① Direct renin inhibitors, ② ACE Inhibitors, ③ARBs, ④ Aldosterone antagonists.

Ang II is the effector enzyme of the cascade and most biological actions of Ang II are mediated primarily through type-1 (AT1), and type II (AT2) receptors. In human activation of AT1 receptor causes vasoconstriction via activation of phospholipase and inhibition of adenylate cyclase. Increased blood pressure, promotes adrenal aldosterone secretion, renal sodium reabsorption and release of catecholamine from the adrenal medulla and prejunctional nerve endings [8]. In contrast activation of AT2 receptor causes vasodilation via cGMP dependent pathway [9].

In addition to the Ang I and II, other bioactive angiotensin peptides have been determined in the last decade as: angiotensin III (Ang III), angiotensin IV (Ang IV) and angiotensin 1-7 (Ang 1-7), among of which Ang (1-7) is much more important [10]. Ang (1-7) opposes the vasoconstrictor actions of Ang II by stimulating vasodilator prostaglandins from vascular endothelial and smooth muscle cells [11,12], releasing nitric oxide (NO) [13] and inhibiting vascular cell growth [14]. Furthermore, potentiation of bradykinin at its receptors by binding to the active site of ACE was shown [15]. In addition to vascular bed, Ang (1-7) is also formed in the kidney by the activation of neutral endopeptidases, and its action depends on the state of sodium and water balance, renal nerve activity and RAAS activation [16]. According to the study conducted by Santos et al. Ang (1-7) participates in the control of hydroelectrolyte balance by influencing especially water excretion via both arginine vasopressin (AVP) dependent and independent pathways [17]. These effects of Ang (1-7) presumed to be mediated by a unique receptor known as the Mas receptor (Mas-oncogene) that does not bind to Ang II [18].

In recent years, in addition to the physiological role of systemic RAAS in in the regulation of fluid and electrolyte balance, arterial pressure together with pathological role in CV and renal diseases, studies have focused on the local tissue RAAS in the brain, heart, peripheral blood vessels, adrenal glands and kidney [19-23]. In these vital organs RAAS act as paracrine or autocrine systems both in physiological and pathophysiological conditions. For example, stimulation of intrarenal RAAS plays an important role both in minute-to-minute regulation of sodium reabsorption and in the pathophysiology of sodium retention states such as hypertension and congestive heart failure [24]. Again, inappropriate activation of RAAS in the kidney contributes the nephropathy in patients with diabetes [25,26]. The role of vascular RAAS in the pathogenesis of inflammation, atherosclerosis, hypertrophy, remodeling, and angiogenesis is also known [27,28].

Therefore both circulatory and local RAAS inhibition is a key therapeutic approach to slow progression of chronic kidney disease (CKD) and to reduce CV risk through both blood pressure dependent and independent mechanisms.

RAAS Inhibitors and Need of Direct Renin Inhibition

As seen in the Figure 1 there are now 4 ways to inhibit the RAAS. Among two of them are ACEI and ARBs. Both of them target the Ang II as therapeutic effect, however their mechanisms of action are different. While ACEIs inhibit the ACE enzyme, which converts Ang I to Ang II, ARBs block Ang II to binds its receptors of AT1. Therefore the differences in their mechanisms of action might have their therapeutic implications [29].

Nowadays, blockade of RAAS with ACEIs, ARBs or combination of these drugs underlies the current antihypertensive therapy. The beneficial effects of these agents are attributed to their preventative effects on Ang II mediated vasoconstriction, water and salt retention, aldosterone and vasopressin release, stimulation of sympathetic nervous system, inflammation and stimulation of cell growth [30]. However, inhibition of RAAS with ACEIs or ARBs has proven effective for controlling hypertension most important handicap of these agents is incomplete blockage of RAAS. A fundamental reason is reduced feedback inhibition of renin release, triggering a reactive rise in plasma renin activity [31,32]. With an ACEIs, the reactive rise in plasma renin activity causes compensatory increase in Ang I, which partially restores Ang II production by both ACE-dependent and independent pathways (ACE-escape phenomenon) [33]. With an ARB, the reactive rise in plasma renin activity causes compensatory increases in both Ang I and II. This may partially restore AT1, AT2 and AT4 receptors. In contrast, the direct renin inhibitor binds directly to the catalytic site of renin, thereby inhibiting its ability to convert angiotensinogen to Ang I, the rate-limiting step in the formation of angiotensin II Figure (1) [34,35]. By this complete blockage of RAAS at its origin, decrease in both Ang I and Ang II levels can be achieved by DRIs. Although blocking feedback inhibition causes reactive rise in renin secretion, plasma renin activity (PRA), the enzymatic activity of renin is markedly reduced by the DRI [36]. Therefore, through this more complete RAAS inhibition, DRIs can offer greater protection from hypertensive complications [37].

A second issue with ACEIs and ARBs is that they may not provide effective inhibition of tissue RAAS activity [38,39]. Circulating renin can be taken up by cardiac and coronary tissues, leading to long lasting generation of Ang II via both ACE dependent and independent pathways that is only partially suppressed by ACEIs (Figure 1) [38,40]. While under physiological conditions, the function of the cardiac RAAS is to maintain cellular balance by inhibiting and inducing cell growth, and proliferation and mediation of adaptive responses to myocardial stretch [28] pathologic activation of cardiac RAAS has been proposed to contribute to the development of left ventricular hypertrophy. Similarly activation of vascular RAAS plays a role in the endothelial dysfunction, vascular smooth muscle cell growth, and production of reactive oxidative species that have been associated with inflammation, atherosclerosis, hypertrophy, remodeling, and angiogenesis [28].

Direct Renin Inhibitors: Aliskiren

In addition to being a rate-limiting step in the formation of Ang II, renin is also a good substrate for the inhibition of angiotensinogen. Moreover identification of renin receptors both in the glomerulus and in the artery gives additional advantages of renin inhibition for cardiovascular and renal protection [41]. On one hand binding of renin to its receptor starts the angiotensinogen cascade, on the other hand converts inactive prorenin to an active form. Binding of renin/prorenin to its receptors exerts physiological effects independent from Ang II including activation of intracellular signal pathways, enhanced synthesis of DNA, and stimulation of the release of plasminogen activator inhibitor 1, collagen 1, fibronectin, and transforming growth factor β-1 [42].

The first synthetic renin inhibitor was pepstatin, which was followed by first-generation agents that were active but required parenteral administration [43]. In 1980s, first orally active direct renin inhibitor (DRI) compounds were developed, such as enalkiren, remikiren, and zankiren. Because of their poor bioavability (less than 2%), short half-lives and weak antihypertensive activity they had limited clinical use [44,45]. Later highly potent and selective, non-peptide, low molecular weight DRIs have been synthetized [46,47]. Aliskiren is the first of this new non-peptide, orally effective DRI to be approved by the FDA and by EMEA in 2007 for the treatment of hypertension.

Preclinical development

Aliskiren acts as a competitive renin inhibitor (inhibitory concentration 50%: 0.6 nmol/L), by binding to the enzymatically active site of renin [35,48], which is highly specific for human and primate renin [49]. This makes it to difficult to carry out experimental studies. Therefore it was tested in marmosets and in transgenic rats. According to these studies the oral administration of aliskiren resulted in sustained decrease in mean BP, increase in plasma renin concentration (PRC) and strong inhibition of plasma renin activity (PRA) [50]. This BP lowering effect was also stronger and longer period than benazepril or valsartan [50] Beyond blood pressure lowering effect, end-organ protective effect of aliskiren was also shown in experimental settings. Experiments in a rat model of severe hypertension and organ damage, aliskiren administration reduced proteinuria, reversed cardiac hypertrophy and reduced macrophage infiltration in the heart and kidney. [49,51]. These results provide the proof of organ protective effects of aliskiren.

Pharmacokinetic and pharmacodynamics of aliskiren

In the pharmacokinetic studies, after oral administration of aliskiren a dose dependent increase in the plasma concentration with a peak concentration after 3-6 hours was reported. Other reported pharmacokinetic parameters can be summarized as: the mean absolute bio-availability is 2.6% [52], the peak plasma concentration is reached 1–2 hours after dosing and steady state is reached after 5–8 days of once-daily administration [36], plasma half-life is 23.7 hours [49], and it is eliminated via biliary excretion as unmetabolized drug [45]

According to the pharmacodynamic studies carried out, in patients with hypertension, sustained BP reduction over the 24 h was reported by aliskiren [53]. This was attributed its long plasma half-life (approximately 40 h) [36]. Aliskiren is generally well tolerated, with a placebo like profile. Most commonly reported adverse effects are headache, diarrhea, dizziness, fatigue, and back pain; the frequencies of these effects are similar to both ARBs and placebo [54]. Furthermore because of having no interaction with metabolism of substance P and bradykinin, cough and angioedema like adverse effects caused by the use of ACEIs, do not occur with aliskiren treatment [55,56]. The hepatic elimination of aliskiren also makes it suitable for patients with impaired renal function [45]. Again aliskiren does not interfere with several agents, including warfarin, digoxin, statins and other antihypertensive agents [57,44,58].

Although aliskiren appears to be safe, serum potassium levels must be monitored in patients with renal impairment [49] especially in combination therapy with ACEI and/or ARBs [59] or in patients receiving cyclooxygenase (COX) inhibitors [60].

Clinical efficacy of aliskiren in the light of new evidences

Essential hypertension. Early phase II clinical trials with aliskiren compared the BP-lowering effect and safety of aliskiren with placebo, losartan and irbesartan [61,62].

According to the multicenter, randomized phase III clinical trials, combining aliskiren with drugs that produce a reactive increase in PRA, such as diuretics, ACEIs and ARBs, increases the antihypertensive efficacy of aliskiren [63-66]. In a study conducted by Villamil and colleagues combination therapy of HCTZ and aliskiren was superior to both monotherapies in reducing both systolic and diastolic blood pressure with a 46.1–63.5% decrease in PRA [65]. Moreover aliskiren/HCTZ combination showed similar tolerability to aliskiren monotherapy [67]. The efficacy, safety and tolerability of combination therapy with aliskiren and ACEIs have also been shown [59,63]. Again combination therapy with aliskiren and ARBs; the decrease in diastolic blood pressure was statistically significant than either monotheraphy alone without any increase in the rate of adverse effects. Furthermore incidents of hyperkalemia and increased serum creatinine levels were similar in all groups and did not demand discontinuation of treatment [63]. Similarly in the ACCELERATE trial, the decrease in the systolic blood pressure was significant when aliskiren combined with the amlodipine without additional adverse event [59].

Parallel with these findings; previous meta-analysis showed the safety and tolerability of aliskiren in combination with the ARBs, or diuretic, is similar to aliskiren, ARBs, or diuretics alone [68]. The analysis results confirmed that the combination therapy of aliskiren with ARB in adult patients with hypertension was associated with significantly better compliance, fewer hospitalizations and medical visits compared with ACEI/ARB combination [69]. On contrary according to the meta-analysis conducted by Harel et al, combination therapy of aliskiren/ACEIs or ARBs significantly increased the risk of hyperkalemia compared with monotherapy [70].

Prevention of end-organ damage. The cardio-renal protecting effects of aliskiren was evaluated with the ASPHIRE HIGHER program that consisted of 14 multicenter phase III clinical trials including more than 35.000 patients with hypertension, diabetes, HF, renal dysfunction, and previous MI [71].

Hypertension and congestive heart failure. The ALOFT study conducted in patients with hypertension who had stable heart failure (HF) briefly showed that adding aliskiren to the standard therapy (ACEIs, ARBs and beta blockers (BBs) produces reduction in brain natriuretic peptide (BNP), N-terminal proBNP, aldosterone and renin levels, improvement in left ventricular (LV) function as well as comparable tolerability [72]. Similar results were also shown both in AVANT-GARDE trial for the aliskiren/valsartan combination [73] and in ALLAY trial for the aliskiren/losartan combination [74]. According to the ASPIRE study, with the addition of aliskiren to an ARBs or an ACEIs there was no differences in LV volume and function after MI. Furthermore higher rates adverse events were seen with aliskiren [74]. Same results were also shown for ARB/ACEI combinations both in ONTARGET and VAILANT trials [75].

Hypertension and diabetes. According to the AVOID study, addition of aliskiren to the losartan showed the renoprotective effect by reduction in proteinuria. This effect was also independent from BP reduction [76]. Similar cardio-renal protective effects were shown with the addition of aliskiren to ACEI or ARB conventional therapy in the ALTITUDE trial, in patients with II diabetes [77]. However the study was early terminated as a result of higher adverse events (renal complications, increased incidence of nonfatal stroke and hyperkalemia). After termination of the study both EMA and FDA contraindicated the use of dual RAAS blockade with aliskiren in diabetic patients and patients with moderate-to-severe renal failure [78,79].

Hypertension and chronic disease. Early phase II studies showed the effectiveness of aliskiren in patients with CKD [64] unfortunately its use in the diabetic nephropathy gave disappointing results in the ALTITUDE study [77]. Here, we have to point out that there is no long-term comparative study evaluating the effect of direct renin inhibition in renal function with ACEI/ARBs especially in progressive renal injury.

Possible explanation for the controversial results of dual RAAS blockage with aliskiren

Controversial results were reported for the dual RAAS system blockage by ACEI and ARBs [80-83]. Similar controversy exists for aliskiren. While beneficial effect of aliskiren/losartan combination was shown in ALLAY trial [74], the result of ALTITUDE trial was disappointing [77]. According to Dr. Juncos, an investigator of ALTITUDE study, one possible explanation of this controversy is the unspecified use of dual RAAS blockage. For example using of dual RAAs blockage in patients with almost normal BP. The baseline BP values were: 142/82 mmHg and 137/74 mmHg for ONTARGET and ALTITUDE trials respectively. Dual RAAS inhibition with patients lower than basal BP levels could cause hypo perfusion of heart, brain or kidney. Observing of hypotensive episodes with the addition of aliskiren to the ACEI and/or ARB monotherapy in ALTITUDE trail, especially in patients with lower pulse pressure or patients who were older than 65 years of age supports this argument [84]. Again related to the hyperkalemia, a well-known complication of poor organ perfusion, similar argument can be done. In ALTITUDE trial, patients with the basal serum potassium concentration greater than 5mEq/l were randomized to the combination therapy arm. Although combination therapy significantly increased the risk of hyperkalemia (relative risk 1.58 %), this was clinically insignificant. (< 6 mEq/l) [70,84]. As a result, Dr. Junos claims that aliskiren could not be used as add-on therapy to ACEI or ARBs in patients with nearly normal BP and with serum potassium levels higher than 5mEq/l [84].

Regarding the increased stroke risk, through the analysis of ONTARGET database Mann and colleagues [75] showed the association of blood pressure lowering intervention with a reduction in stroke rate for diabetic patients. However, in patients with prior stroke it was suggested as a potential harm with BP below 120 mmHg systolic [85]. Parallel to this evidence, though the early results of ALTITUDE study showed an increase in nonfatal stroke (112 cases were in aliskiren and 85 cases were in placebo group, hazard ratio was 1.34, 95 % CI), all data analysis done by Harel showed a small relative difference (146 and 118 were in respectively, the hazard ratio was 1.25, 95 % CI) [70].

Regarding the CKD, the risk of stroke is known to increase with CKD [86]. Furthermore, there is evidence with strong relationship of blood pressure and stroke in CKD [87]. Based on the evidence it would be argued that an antihypertensive therapy could be more protective for stroke in CKD [75]. Moreover, it is well known that increased protein excretion rate is a key parameter in the progression of kidney disease [88]. Therefore, in addition to blood pressure control, additional goal must be the reduction of proteinuria in CKD [84]. The renoprotective effect of aliskiren by reducing proteinuria is known. It is also shown that this effect is independent from BP reducing effect of aliskiren [76].

New Molecular Mechanisms of Aliskiren

Although clinical trials related to the organoprotective potential of aliskiren gave controversial results, new studies on molecular based show the organoprotective potential of aliskiren beyond its antihypertensive action.

As discussed earlier, renin catalyses the hydrolysis of angiotensinogen to form Ang I that is subsequently converted to the biologically active Ang II by the help of ACE. Renin is formed from the prorenin. Both prorenin and renin bind to the (pro) renin receptor (PRR) result in PRR-mediated effect of renin, independent from Ang-II [89]. The functional link of PRR to the vacuolar-H+-ATPase (v-H+-ATPase) that regulates pH of cellular and intracellular vesicles, and to Wnt/frizzled (Wnt/Fz) signalling is known. Moreover the physiological role of this signalling pathway in the cell survival and embryonic development together with the pathophysiological role in various disease like chronic kidney diseases, malignancy, infection, endocrine disorders, hypertension and diabetes was shown [90]. Hence PRR down regulatory potential of aliskiren opens up new areas of research beyond hypertension. Indeed aliskiren induced reduction induced reduction in PRR gene expression was shown in diabetic TG(mRen-2)27 rats [91] and cultured human aortic smooth muscle cells [92].

The peroxime proliferator-activated receptor (PPARγ) activated role of RAAS in the attenuation of the development of hypertension, endothelial dysfunction and inflammation has been shown [93,94]. The endothelial nitric oxide (eNOS) activating effects of PPARγ in the prevention of cardiovascular disorders has also been shown [90]. Furthermore the Wnt/Fz mediated regulation of PPARγ transcription factor has been shown [95]. Therefore aliskiren might up regulate and activate PPARγ signaling via Wnt pathway resulted in increasing NO formation through eNOS activation. This in turn might afford CV protection and improve vascular endothelial function [90]. Improvement of impaired NO bioavailability and the protection against atherosclerotic changes in the vascular endothelium of Watanabe heritable hyperlipidemic rabbits was shown by aliskiren [96]. Again protective effect of aliskiren in the hypertensive organ injury caused by eNOS dysfunction was shown in eNOS-deficient mice [97]. Because these molecular mechanisms were shown in the in-vitro and/or in-vivo animal studies, they need to be proven in further clinical studies with larger sample size.


RAAS plays a vital role in the pathophysiology of hypertension and cardio-renal disorders. Ang II is the key component of RAAS. The intervention to the RAAS can be achieved in different stages. While ACEI and ARBs are the traditional blockers, aliskiren a direct renin inhibitor was launched as a new class of inhibitor. Although earlier small-scale clinical trials indicated a possible positive effectiveness, later large-scale trails were disappointing. As a consequence, both EMA and FDA terminated the use of dual RAAS blockage with aliskiren in diabetic patients and patients with moderate-to-severe renal failure. However, later metaanalysis showed evidence of the cardio-renal protective effect of aliskiren. Recently, the results of the invitro/in-vivo animal studies have also displayed new possible molecular mechanisms of aliskiren. With large size clinical trials to prove the new molecular mechanism of aliskiren, controversial results on the cardio-renal protecting effects of aliskiren would be solved.


  1. Werner C, Baumhakel M, Teo KK, Schmieder R, Mann J, et al. (2008) RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol 97: 418-431.
  2. Turnbull F (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomized trials.Lancet 362: 1527-1535.
  3. Nguyen G, Burckle C, Sraer JD (2003) The renin receptor: the facts, the promise and the hope. Curr Opin Nephrol Hypertens 12: 51-55
  4. Laragh JH, Sealey JE (2003) Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and evaluating ALLHAT. Am J Hypertens 16: 407-415
  5. Skeggs LT, Kahn JR, Lentz K, Shumway NP (1957) Preparation, purification, and amino acid sequence of polypeptide renin substrate. J Exp Med 106: 1449-1456.
  6. Levy BI (2009) Are there differences between the RAAS inhibitors? Medicographia 31: 16-23.
  7. Carey RM, Siragy HM (2003) Newly recognized components of the renin-angiotensin system: Potential roles in cardiovascular and renal regulation. Endocr Rev 24: 261-271.
  8. Kim S, Iwao H (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52: 11-34.
  9. Abassi Z, Winaver J, Feuerstein GZ (2009) The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. Biochem Pharmacol 78: 933-940.
  10. Carey RM, Siragy HM (2003) Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24: 261-271.
  11. Muthalif MM, Benter IF, Uddin MR, Harper JL, Malik KU (1998) Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. J Pharmacol Exp Ther 284: 388-398.
  12. Jaiswal N, Diz DI, Chappell MC, Khosla MC, Ferrario CM (1992) Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension 19: II49-55.
  13. Li P, Chappell MC, Ferrario CM, Brosnihan KB (1997) Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 29: 394-400.
  14. Ueda S, Masumori-Maemoto S, Ashino K, Nagahara T, Gotoh E, et al. (2000) Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension 35: 998-1001.
  15. Paula RD, Lima CV, Khosla MC, Santos RA (1995) Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 26: 1154-1159.
  16. Chappell MC, Diz DI, Yunis C, Ferrario CM (1998) Differential actions of angiotensin-(1-7) in the kidney. Kidney Int Suppl 68: S3-6.
  17. Santos RA, Simões e Silva AC, Magaldi AJ, Khosla MC, Cesar KR, et al. (1996) Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Hypertension 27: 875-884.
  18. Stanton A1 (2003) Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 3: 389-394.
  19. Dell'Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R, et al. (1997) Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest 100: 253-258.
  20. Muller DN, Bohlender J, Hilgers KF, Dragun D, Costerousse O, et al. (1997) Vascular angiotensin-converting enzyme expression regulates local angiotensin II. Hypertension 29: 98-104.
  21. Dostal DE (2000) The cardiac renin-angiotensin system: novel signaling mechanisms related to cardiac growth and function. Regul Pept 91: 1-11.
  22. Johnston CI (1992) Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl 10: S13-26.
  23. Pool JL (2007) Direct renin inhibition: focus on aliskiren. J Manag Care Pharm 13: 21-33.
  24. Carey RM, Siragy HM (2003) Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24: 261-271.
  25. Hollenberg NK, Price DA, Fisher ND, Lansang MC, Perkins B, et al. (2003) Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 63: 172-178.
  26. Taniwaki H, Ishimura E, Kawagishi T, Matsumoto N, Hosoi M, et al. (2003) Intrarenal hemodynamic changes after captopril test in patients with type 2 diabetes: a duplex Doppler sonography study. Diabetes Care 26: 132-137.
  27. Sata M, Fukuda D (2010) Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J Med Invest 57: 12-25.
  28. Paul M, Poyan Mehr A, Kreutz R (2006) Physiology of local renin-angiotensin systems. Physiol Rev 86: 747-803.
  29. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, et al. (2008) Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118: 2523-2532.
  30. Unger T (2002) The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89: 3A-9A.
  31. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, et al. (1990) Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 15: 276-282.
  32. Azizi M, Ménard J (2004) Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 109: 2492-2499.
  33. Shafiq MM, Menon DV, Victor RG (2008) Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 121: 265-271.
  34. Danser AH, Deinum J (2005) Renin, prorenin and the putative (pro)renin receptor. Hypertension 46: 1069-1076.
  35. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC et al. (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308: 698-705.
  36. Nussberger J, Wuerzner G, Jensen C, Brunner HR (2002) Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39: E1-8.
  37. O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, et al. (2007) Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 49: 276-284.
  38. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlöf B, et al. (2002) Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 16: 149-160.
  39. Muller DN, Fischli W, Clozel JP, Hilgers KF, Bohlender J, et al. (1998) Local angiotensin II generation in the rat heart: role of renin uptake. Circ Res 82: 13-20.
  40. Levy BI (2005) How to explain the differences between renin angiotensin system modulators. Am J Hypertens 18: 134S-141S.
  41. Oliver JA (2006) Receptor-mediated actions of renin and prorenin. Kidney Int 69: 13-15.
  42. Jan Danser AH, Batenburg WW, van Esch JH (2007) Prorenin and the (pro)renin receptor--an update. Nephrol Dial Transplant 22: 1288-1292.
  43. Gross F, Lazar J, Orth H (1972) Inhibition of the renin-angiotensinogen reaction by pepstatin. Science 175: 656.
  44. Staessen JA, Li Y, Richart T (2006) Oral renin inhibitors. Lancet 368: 1449-1456.
  45. Fisher ND, Hollenberg NK (2005) Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 16: 592-599.
  46. Oefner C, Binggeli A, Breu V, Bur D, Clozel JP, et al. (1999) Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases? Chem Biol 6: 127-131.
  47. Rahuel J, Rasetti V, Maibaum J, Rüeger H, Göschke R, et al. (2000) Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 7: 493-504.
  48. Wood JM, Baum HP, Jobber RA, Neisius D (1987) Sustained reduction in blood pressure during chronic administration of a renin inhibitor to normotensive marmosets. J Cardiovasc Pharmacol 10 Suppl 7: S96-98.
  49. Azizi M, Webb R, Nussberger J, Hollenberg NK (2006) Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 24: 243-256.
  50. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL (2005) Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 23: 417-426.
  51. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, et al. (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46: 569-576.
  52. Vaidyanathan S, Warren V, Yeh C, Bizot MN, Dieterich HA, et al. (2007) Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 47: 192-200.
  53. Verdecchia P, Angeli F, Mazzotta G, Martire P, Garofoli M, et al. (2010) Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis 4: 193-200.
  54. Ferro A, Gilbert R, Krum H (2006) Importance of renin in blood pressure regulation and therapeutic potential of renin inhibition. Int J Clin Pract 60: 577-581.
  55. Novartis Pharmaceutical Corporation (2007) Tekturna (aliskiren) prescribing information.
  56. Strasser RH, Puig JG, Farsang C, Croket M, Li J, et al. (2007) A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 21: 780-787.
  57. Dieterich H, Kemp C, Vaidyanathan S (2006) Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther 79: 111-124.
  58. Vaidyanathan S, Valencia J, Kemp C (2006) Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensive amlodipine, valsartan, hydrochlorothiazide (HTCZ) and ramipril in healthy volunteers. Int J Clin Pract 60: 1343-1356.
  59. Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, et al. (2007) Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 8: 190-198.
  60. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, et al. (2003) Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 107: 1401-1406.
  61. Gradman AH, Schmieder RE, Lins RL, et al (2005). Aliskiren, a novel, orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an AT1-receptor blocker in hypertensive patients. Circulation 111:1012–1018.
  62. Stanton A, Jensen C, Nussberger J, O'Brien E (2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42: 1137-1143.
  63. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, et al. (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370: 221-229.
  64. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, et al. (2008) Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 26: 589-599.
  65. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, et al. (2007) Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 25: 217-226.
  66. Gradman A, Schmieder R, Lins R, Nussberger J, Chian Y et al. (2005) Antihypertensive aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111: 1012-1018.
  67. Nickenig G, Simanenkov V, Lembo G, Rodriguez P, Salko T, et al. (2008) Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Press Suppl 2: 31-40.
  68. White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, et al. (2011) Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients. J Clin Hypertens 13:506-516.
  69. Chang J, Yang W, Kahler KH, Fellers T, Orloff J, et al. (2011) Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension. Am J Cardiovasc Drugs 11: 21-32.
  70. Harel Z, Gilbert C, Wald R, Bell C, Perl J, et al. (2012) The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 344: e42.
  71. ASPIRE HIGHER clinical program expands 2010
  72. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, et al. (2008) Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1: 17-24.
  73. Scirica BM, Morrow DA, Bode C, Ruzyllo W, Ruda M, et al. (2010) Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J 31: 1993-2005.
  74. Solomon SD (2010) Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with left ventricular dysfunction: ASPIRE. Presented at: American College of Cardiology 59th Annual Scientific Sessions; March 13-16, 2010; Atlanta, GA.
  75. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, et al. (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553.
  76. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446.
  77. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, et al. (2009) Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24: 1663-1671.
  78. European Medicines Agency
  79. U.S. Food and Drug Administration.
  80. Mogensen C, Neldam S, Tikkanen I, Oren S, Viskoper R et al. (2000) Randomised controlled trial of dual blockade of renin angiotensin system in patients with hypertension, micro albuminuria and non-insulin dependent diabetes: the candesartan and lisinopril micro albuminuria (CALM) study. Br Med J 321: 1440-1444.
  81. Nakao N, Seno H, Kasuga H, Toriyama T, Kawahara H, et al. (2004) Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy. Am J Nephrol 24: 543-548.
  82. Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148: 30-48.
  83. Yusuf S, Teo K, Pogue J (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559.
  84. Juncos L (2013) Direct renin inhibition: extricating facts from façades. Ther Adv Cardiovasc Dis 7: 153-167.
  85. Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, et al. (2011) Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 306: 2137-2144.
  86. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134: 629-636.
  87. Kokubo Y, Nakamura S, Okamura T, Yoshimasa Y, Makino H, et al. (2009) Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the Suita Study. Stroke 40:2674-2679.
  88. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869.
  89. Nguyen G, Danser AH (2006) The (pro)renin receptor: therapeutic consequences. Expert Opin Investig Drugs 15: 1131-1135.
  90. Balakumar P, Jagadeesh G (2011) Potential cross-talk between (pro)renin receptors and Wnt/frizzled receptors in cardiovascular and renal disorders. Hypertens Res 34: 1161-1170.
  91. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, et al. (2008) Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52: 130-136.
  92. Ferri N, Greco CM, Maiocchi G, Corsini A (2011) Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells. J Renin Angiotensin Aldosterone Syst 12: 469-474.
  93. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, et al. (2001) Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142: 3125-3134.
  94. Hinrichs S, Heger J, Schreckenberg R, Wenzel S, Euler G, et al. (2011) Controlling cardiomyocyte length: the role of renin and PPAR-{gamma}. Cardiovasc Res 89: 344-352.
  95. Jagadeesh G, Balakumar P, Stockbridge N (2012) How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders? Cell Signal 24: 1583-1591.
  96. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, et al. (2008) Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 52: 563-572.
  97. Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, et al. (2009) Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 54: 633-638.
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11721
  • [From(publication date):
    July-2015 - Aug 21, 2017]
  • Breakdown by view type
  • HTML page views : 7947
  • PDF downloads :3774

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version